Previous studies have highlighted that α7-nAChR modulators can minimise the extent of cell death [18,19] and enhance synaptic plasticity [20], making α7-nAChRs an ideal therapeutic target for several neurological diseases including depression, Parkinson’s disease, schizophrenia and Alzheimer’s disease [21]. Here, CHRNA7 is linked to depressive disorder.